Clinical Trial Details
Braintumor Website

[Information provided by:, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT00898755 : Collecting and Storing Tissue From Young Patients With Cancer
AgesMin: N/A Max: 21 Years

- All malignant tissues from childhood cancers allowed including the following:

- Brain tumors (all types)

- Tissue should be submitted to CNS Committee Resource labs to be forwarded
for this study, unless instructed otherwise on the COG web site

- Ewing family of tumors

- Rhabdomyosarcomas

- Other soft tissue sarcomas

- Osteogenic sarcomas

- Rhabdoid tumors

- Neuroblastomas

- Viable material for cell culture for neuroblastoma is collected via
COG-ANBL00B1 and should not be submitted via this study unless the patient
cannot be enrolled on COG-ANBL00B1* NOTE: *The same applies to any similar
biology studies from other disease committees

- Retinoblastomas

- Anaplastic Wilms tumor

- Germ cell tumors

- Leukemias/lymphomas

- Acute myeloid leukemia (AML)

- Blood samples and bone marrow samples from patients at second relapse
and beyond may be submitted for this study

- Bone marrow samples at diagnosis or first relapse must be submitted to
an AML resource lab and will be forwarded for this study at the
discretion of the AML Committee

- Acute lymphoblastic leukemia (ALL)

- Blood samples may be submitted directly to this study

- Bone marrow samples must be submitted to an ALL resource lab and will
be forwarded for this study at the discretion of the ALL Committee

- Enrolled on a COG therapeutic, biology, or tissue banking protocol that allows
collection of tissue for research and submission to a COG-designated resource

- Participation in this protocol is not permitted until after tissue requirements
for any active COG disease-specific therapeutic, biology, or banking protocols
have been satisfied

- Material may only be submitted for this protocol if tissue is available in excess
of that required for satisfying active disease-specific therapeutic and
biological protocols

- Patients with diagnosis pending are eligible


- Not specified


- Not specified
LinksPermanent Link to THIS page:      |      Link to official listing

Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2018 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557